Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Large Increase in Short Interest

Hoth Therapeutics, Inc. (NASDAQ:HOTH) saw a large increase in short interest in September. As of September 15th, there was short interest totalling 245,300 shares, an increase of 11.8% from the August 31st total of 219,400 shares. Currently, 3.6% of the company’s stock are sold short. Based on an average trading volume of 3,650,000 shares, the short-interest ratio is presently 0.1 days.

Hoth Therapeutics Trading Down 2.3 %

NASDAQ:HOTH traded down $0.02 during midday trading on Tuesday, hitting $0.86. 82,251 shares of the stock were exchanged, compared to its average volume of 1,446,646. The business has a 50-day moving average price of $0.82 and a two-hundred day moving average price of $1.03. The company has a market capitalization of $4.61 million, a price-to-earnings ratio of -0.44 and a beta of 0.82. Hoth Therapeutics has a one year low of $0.58 and a one year high of $1.73.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.15. Sell-side analysts forecast that Hoth Therapeutics will post -1.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on HOTH. EF Hutton Acquisition Co. I upgraded shares of Hoth Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Hoth Therapeutics in a research note on Friday, August 16th.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.